New tracers beyond FDG in head and neck oncology

Area of Science:

• Nuclear Medicine
• Oncology
• Radiochemistry

Background:

• Positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG-PET) is a standard imaging technique for staging and re-staging head and neck squamous cell carcinomas (HNSCC).
• FDG-PET offers high sensitivity for HNSCC detection due to intense glucose uptake but suffers from limitations like physiological uptake in normal tissues and non-specific uptake in inflammatory processes.
• These limitations necessitate the development of novel PET tracers to improve diagnostic accuracy and therapeutic monitoring in HNSCC.

Purpose of the Study:

• To evaluate the potential of novel PET tracers targeting amino acid transport, thymidine metabolism, hypoxia, and antigen expression as alternatives or complements to FDG-PET for HNSCC management.
• To assess the sensitivity and specificity of these new tracers in preclinical and initial clinical studies.
• To determine if these advanced PET agents can provide complementary information to FDG-PET, enhancing tumor detection, proliferation assessment, and treatment response monitoring.

Main Methods:

• Review of preclinical and initial clinical studies investigating novel PET tracers for HNSCC.
• Analysis of tracers targeting specific biological processes including amino acid transport, cell proliferation (thymidine metabolism), tumor hypoxia, and antigen expression (e.g., alpha(v)beta(3) integrins).
• Comparison of the diagnostic performance (sensitivity, specificity) of novel tracers against established FDG-PET imaging.

Main Results:

• New PET tracers targeting amino acid transport, proliferation, hypoxia, and antigen expression have shown encouraging preliminary results in small patient cohorts.
• Despite promising findings, none of the investigated tracers demonstrate sufficient sensitivity to replace FDG-PET for primary staging and re-staging of HNSCC.
• Amino acid tracers may offer improved specificity for HNSCC detection, while [18F]fluorothymidine PET shows potential for monitoring therapy-induced proliferation changes.
• Hypoxia markers could guide radiotherapy by identifying radioresistant tumor regions, and radiolabeled antibodies may enable targeted therapy monitoring.

Conclusions:

• While novel PET tracers show potential for complementary roles in HNSCC management, they are unlikely to supersede FDG-PET for initial staging and re-staging due to limited sensitivity.
• These advanced PET agents may provide valuable additional information, aiding in more specific tumor detection, assessing treatment response, and guiding radiotherapy.
• Further systematic clinical studies are essential to validate the utility of these promising PET tracers before their integration into routine patient care for HNSCC.